According to a report from the Tufts Center for the Study of Drug Development, it takes an average of 10 years for an investigational drug to make it from the laboratory to pharmacy shelves. Only five in 5,000 compounds that enter preclinical testing make it to human clinical trials, and of these five, only one is approved by the FDA.
This means that as a participant – and even as a clinical research site – it is often years before you see the treatment that was being studied actually receive approval from the FDA. Therefore, when we do learn of approvals for drugs on which studies our sites have participated, we want to be sure to share them. Below are some recent FDA approvals where PMG sites participated in the clinical research.
- Genentech Actemra (tocilizumab) for moderately to severely active rheumatoid arthritis (approved in subcutaneous formulation)
- Sunovion Pharmaceuticals Aptiom for epilepsy
- GlaxoSmithKline ANORO ELLIPTA for airflow obstruction in COPD patients
- GlaxoSmithKline H5N1 influenza vaccine
Thank you to our patient volunteers, sites, and physician investigators
who participated in these studies!